Evaluation of glycine site antagonists of the NMDA receptor in global cerebral ischaemia

Brain Research

Volumn 819, Issue 1-2, 1999, Pages 65-74

  Hicks, Caroline A ^a   Ward, Mark A ^a   Ragumoorthy, Nella ^a   Ambler, Samantha J ^a   Dell, Colin P ^a   Dobson, David ^a   O'Neill, Michael J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

324; ACEA1021; Cerebral ischaemia; Gerbil; Glycine site antagonist; GV150526A; L 701; LY293558; Neuroprotection

Indexed keywords

3 AMINO 1 HYDROXY 2 PYRROLIDINONE; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; 7 CHLORO 4 HYDROXY 3 (3 PHENOXYPHENYL) 2 QUINOLONE; AMPA RECEPTOR ANTAGONIST; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; DIZOCILPINE; GAVESTINEL; GLYCINE RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CAROTID ARTERY OBSTRUCTION; CELL LOSS; CONTROLLED STUDY; DRUG EFFECT; GERBIL; HIPPOCAMPUS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANIMALS; ARTERIAL OCCLUSIVE DISEASES; CAROTID ARTERY DISEASES; CELL DEATH; EXCITATORY AMINO ACID ANTAGONISTS; GERBILLINAE; HIPPOCAMPUS; ISCHEMIC ATTACK, TRANSIENT; MALE; NEURONS; NEUROPROTECTIVE AGENTS; RECEPTORS, AMPA; RECEPTORS, GLYCINE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0033585872     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)01329-8     Document Type: Article

References (57)

1. Boast C.A., Gerhardt S.C., Pastor G., Lehmann J., Ethienne P.E., Liebmann J. The N-methyl-D-aspartate antagonist CGS 19755 and CPP reduce ischemic damage in gerbils. Brain Res. 442:1988;345-348.
2. Bordi F., Pietra C., Ziviani L., Reggiani A. The glycine antagonist GV 150526A protects somatosenory evoked potentials and reduces the infarct area in the MCAO model of focal ischemia in the rat. Exp. Neurol. 145:1997;425-433.
3. Bristow L.J., Hutson P.H., Kulagowski J.J., Leeson P.D., Matheson S., Murray F., Rathbone D., Saywell K.L., Thorn L., Watt A.P., Tricklebank M.D. Anticonvulsant and behavioral profile of L-701,324, a potent, orally active antagonist at the glycine modulatory site on the N-methyl-D-aspartate receptor complex. J. Pharmacol. Exp. Ther. 279:1996;492-501.
4. Bullock R., Graham D.I., Swanson S., McCulloch J. Neuroprotective effect of the AMPA receptor antagonist LY 293558 in focal ischemia in the cat. J. Cereb. Blood Flow Metab. 14:1994;466-471.
5. Butcher S.P., Bullock R., Graham D.I., McCulloch J. Correlation between amino acid release and neuropathologic outcome in rat brain following middle cerebral artery occlusion. Stroke. 21:1990;1727-1733.
6. Carling R.W., Leeson P.D., Moore K.W., Moyes C.R., Duncton M., Hudson M.L., Baker R., Foster A.C., Grimwood S., Kemp J.A., Marshall G.R., Tricklebank M.D., Saywell K.L. 4-substituted-3-phenylquinolin-2(1H)-ones: acidic and nonacidic glycine site N-methyl-D-aspartate antagonists with in vivo activity. J. Med. Chem. 40:1997;754-765.
7. Choi D.W., Maulucci-Gedde M., Kriegstein A.R. Glutamate neurotoxicity in cortical cell culture. J. Neurosci. 7:1987;357-368.
8. Choi D.W., Koh J.-Y., Peters S. Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. J. Neurosci. 8:1988;185-196.
9. Collingridge G.L., Lester R.A.J. Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacol. Rev. 40:1989;143-210.
10. Foster A.C., Donald A.E., Willis C.L., Tridgett R., Kemp J.A., Priestley T. The glycine site on the NMDA receptor: pharmacology and involvement in NMDA receptor-mediated neurodegeneration. Adv. Exp. Med. Biol. 268:1990;93-100.
11. Gill R., Foster A.C., Woodruff G.N. Systemic administration of MK-801 protects against ischemia-induced hippocampal neurodegeneration in the gerbil. J. Neurosci. 7:1987;3343-3349.
12. Gill R. The pharmacology of α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate antagonists and their role in cerebral ischaemia. Cerebrovasc. Brain Metab. Rev. 6:1994;225-256.
13. Gill R., Hargreaves R.J., Kemp J.A. The neuroprotective effect of the glycine site antagonist 3R-(+)-cis-4-methyl-HA966 (L-687,414) in a rat model of focal ischaemia. J. Cereb. Blood Flow Metab. 15:1995;197-204.
14. Gill R., Lodge D. The neuroprotective effects of the decahydroisoquinoline, LY 215490; a novel AMPA antagonist in focal ischaemia. Neuropharmacology. 33:1995;1529-1536.
15. Globus M.Y.-T., Busto R., Dietrich W.D., Martinez E., Valdes I., Ginsberg M.D. Effect of ischemia on in vivo release of striatal dopamine, glutamate and gamma-aminobutyric acid studied by intracerebral microdialysis. J. Neurochem. 51:1988;1455-1464.
16. R. Graf, W.-D. Heiss, K. Wienhard, R. Saito, J. Taguchi, K. Matsumoto, K. Hübel, G. Rosner, Excitotoxicity: interaction of neuroactive substances during prolonged focal ischemia in cats, in: J. Krieglstein, H. Oberpichler-Schwenk (Eds.), Pharmacology of Cerebral Ischemia, 1994, pp. 165-176.
17. Graham S.H., Chen J., Lan J.Q., Simon R.P. A dose-response study of neuroprotection using the AMPA antagonist NBQX in rat focal cerebral ischemia. J. Pharmacol. Exp. Ther. 276:1996;1-4.
18. Grotta J.C., Picone C.M., Ostrow P.T., Strong R.A., Earls R.M., Yao L.P., Rhoades, Dedman J.R. CGS 19755, a competitive NMDA receptor antagonist, reduces calcium-calmodulin binding and improves outcome after global cerebral ischemia. Ann. Neurol. 27:1990;612-619.
19. Hargreaves R.J., Rigby M., Smith D., Hill R.G. Lack of effect of L-687,414 ((+)-cis-4-methyl-HA-966, an NMDA receptor antagonist acting at the glycine site, on cerebral glucose metabolism and cortical neuronal morphology. Br. J. Pharmacol. 110:1993;36-42.
20. Hawkinson J.E., Huber K.R., Sahota P.S., Han-Hsu H., Weber E., Whitehouse M.J. The N-methyl-D-aspartate (NMDA) receptor glycine site antagonist ACEA 1021 does not produce pathological changes in rat brain. Brain Res. 744:1997;227-234.
21. Kawasaki-Yatsugi S., Yatsugi S., Koshiya K., Shimizu-Sasamata M. Neuroprotective effect of YM90K, an AMPA-receptor antagonist, against delayed neuronal death induced by transient global cerebral ischemia in gerbils and rats. Jpn. J. Pharmacol. 74:1997;253-260.
22. Kemp J.A., Priestley T. Effects of (+) HA-966 and 7-chlorokynurenic acid on the kinetics of N-methyl-D-aspartate receptor agonist responses in rat cortical neurons. Mol. Pharmacol. 39:1991;666-670.
23. Kemp J.A., Leeson P.D. The glycine site of the NMDA receptor: five years on. Trends Pharmacol. Sci. 14:1993;20-25.
24. Koek W., Woods J.H., Winger G.D. MK-801, a proposed noncompetitive antagonist of excitatory amino acid neurotransmission, produces phencyclidine-like behavioral effects in pigeons, rats and rhesus monkeys. J. Pharmacol. Exp. Ther. 245:1988;969-974.
25. Kurumaji A., Nehls D.G., Park C.K., McCulloch J. Effects of NMDA antagonists, MK-801 and CPP, upon local cerebral glucose use. Brain Res. 496:1989;268-284.
26. B and AMPA antagonists. J. Neural. Transm. 104:1997;1249-1254.
27. Leeson P.D., Baker R., Carling R.W., Curtis N.R., Moore K.W., Williams B.J., Foster A.C., Donald A.E., Kemp J.A., Marshall G.R. Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor. J. Med. Chem. 34:1991;1243-1252.
28. Li H., Buchan A.M. Treatment with an AMPA antagonist 12 h following severe normothermic forebrain ischemia prevents CA1 neuronal injury. J. Cereb. Blood Flow Metab. 13:1993;933-939.
29. Lodge D., Bond A., O'Neill M.J., Hicks C.A., Jones M.G. Stereoselective effects of 2,3-benzodiazepines in vivo: electrophysiology and neuroprotection studies. Neuropharmacology. 35:1996;1681-1688.
30. McCulloch J. Excitatory amino acid antagonists and their potential for the treatment of ischaemic brain damage in man. Br. J. Clin. Pharmacol. 34:1992;106-114.
31. Meldrum B., Garthwaite J. Excitatory amino acids in neurotoxicity and neurodegenerative diseases. Trends Pharmacol. Sci. 11:1990;379-386.
32. Morimoto Y., Wu B., Bart R.D., Morimoto Y., Pearlstein R.D., Warner D.S. Effects of NMDA receptor glycine recognition site antagonism on cerebral metabolic rate for glucose and cerebral blood flow in the conscious rat. Brain Res. 779:1998;170-176.
33. Morris R.G.M., Anderson E., Lynch G.S., Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature. 319:1986;774-0776.
34. Olney J.W., Labruyere J., Price M.T. Pathological changes induced in cerebrocortical neurons by phenyclidine and related drugs. Science. 244:1990;1360-1362.
35. Olney J.W., Labruyere J., Wang G., Wozniak D.F., Price M.T., Sesma M.A. NMDA antagonist neurotoxicity: mechanism and prevention. Science. 254:1991;1515-1518.
36. + channel inhibitors in vitro and in global cerebral ischaemia in vivo. Eur. J. Pharmacol. 332:1997;121-131.
37. O'Neill M.J., Hicks C., Ward M., Panetta J.A. Neuroprotective effects of the antioxidant LY231617 and NO synthase inhibitors in global cerebral ischaemia. Brain Res. 760:1997;170-178.
38. O'Neill M.J., Bond A., Ornstein P.L., Ward M.A., Hicks C.A., Hoo K., Bleakman D., Lodge D. Decahydroisoquinolines: novel competitive AMPA/kainate antagonists with neuroprotective effects in global cerebral ischaemia. Neuropharmacol. 37:1998;1211-1222.
39. Park C.K., McCulloch J., Kang J.K., Choi C.R. Efficacy of D-CPPene, a competitive N-methyl-D-aspartate antagonist in focal cerebral ischemia in the rat. Neurosci. Lett. 147:1992;41-44.
40. Parsons C.G., Danysz W., Quack G., Hartmann S., Lorenz B., Wollenburg C., Baran L., Przegalinski E., Kostowski W., Krzascik P., Chizh B, Headley P.M. Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J. Pharmacol. Exp. Ther. 283:1997;1264-1275.
41. Pearlstein R.D., Beirne J.P., Massey G.W., Warner D.S. Neuroprotective effects of NMDA receptor glycine recognition sites antagonism: dependence on glycine concentration. J. Neurochem. 70:1998;2012-2019.
42. Pelligrini-Giampietro D.E., Cozzi A., Moroni F. The glycine antagonist and free radical scavenger 7-Cl-thio-kynurate reduces CA1 ischemic damage in the gerbil. Neuroscience. 63:1994;701-709.
43. Priestley T., Horne A.L., McKernan R.M., Kemp J.A. The effect of NMDA receptor glycine site antagonists on hypoxia-induced neurodegeneration of rat cortical cell cultures. Brain Res. 53:1990;183-188.
44. Rowley M., Kulagowski J.J., Watt A.P., Rathbone D., Stevenson G.I., Carling R.W., Baker R., Marshall G.R., Kemp J.A., Foster A.C., Grimwood S., Hargreaves R., Hurley C., Saywell K.L., Tricklebank M.D, Leeson P.D. Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists. J. Med. Chem. 40:1997;4053-4068.
45. Sheardown M.J., Nielson E.O., Hansen A.J., Jacobsen P., Honoré T. 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline: a neuro-protectant for cerebral ischemia. Science. 247:1990;571-574.
46. Sheardown M.J., Suzdak P.D., Nordholm L. AMPA, but not NMDA, receptor antagonism is neuroprotective in gerbil global ischaemia. Eur. J. Pharmacol. 236:1993;347-353.
47. Singh L., Donald A.E., Foster A.C., Hutson P.H., Iversen L.L., Iversen S.D., Kemp J.A., Leeson P.D., Marshall G.R., Oles R.J., Priestley T., Thorn L., Tricklebank M.D., Vass C.a., Williams B.J. Enantiomers of HA-966 (3-amino-1-hydroxypyrrolid-2-one) exhibit distinct central nervous system effects: (+) HA-966 is a selective glycine/N-methyl-D-aspartate receptor antagonist, but (-) HA-966 is a potent gamma-butyrolactone-like sedative. Proc. Natl. Acad. Sci. USA. 87:1990;347-351.
48. Smith S.E., Meldrum B.S. Cerebroprotective effect of a non-N-methyl-D-aspartate antagonist, GYKI 52466, after focal ischemia in the rat. Stroke. 23:1992;861-864.
49. Tricklebank M.D., Bristow L.J., Hutson P.H., Leeson P.D., Rowley M., Saywell K., Singh L., Tattersall F.D., Thorn L., Williams B.J. The anticonvulsant and behavioural profile of L-687,414, a partial agonist acting at the glycine modulatory site in the N-methyl-D-aspartate (NMDA) receptor complex. Br. J. Pharmacol. 113:1994;729-736.
50. Umemura K., Shimakura A., Nakashima M. Neuroprotective effect of a novel AMPA receptor antagonist, YM90K, in rat focal cerebral ischaemia. Brain Res. 773:1997;61-65.
51. B receptor antagonists in the amygdala-kindling model in rats. Eur. J. Pharmacol. 342:1998;39-46.
52. Warner D.S., Martin H., Ludwig P., McAllister A., Keana Jt.F.W., Weber E. In vivo models of cerebral ischemia: effects of parentally administered NMDA receptor glycine site antagonists. J. Cereb. Blood Flow Metab. 15:1995;188-196.
53. Watkins J.C., Olverman H.J. Agonists and antagonists for excitatory amino acid receptors. Trends Neurosci. 10:1987;265-272.
54. Wood E.R., Bussey T.J., Phillips A.G. A glycine antagonist reduces ischemia-induced CA1 cell loss in vivo. Neurosci. Lett. 145:1992;10-14.
55. Wood E.R., Bussey T.J., Phillips A.G. A glycine antagonist 7-chlorokynurenic acid attenuates ischemia-induced learning deficits. NeuroReport. 4:1993;151-154.
56. Xue D., Huang Z.-G., Barnes K., Lesiuk H.J., Smith K.E., Buchan A.M. Delayed treatment with AMPA, but not NMDA, antagonists reduces neocortical infarction. J. Cereb. Blood Flow Metab. 14:1994;251-261.
57. Yatsugi S., Takahashi M., Kawasaki-Yatsugi S., Koshiya K., Sakamoto S., Uematsu D., Shimizu-Sasamata M. Neuroprotective effect of YM90K, a novel AMPA/kainate receptor antagonist, in focal cerebral ischemia in cats. J. Cereb. Blood Flow Metab. 16:1996;959-966.